Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line

Citation
K. Kusuzaki et al., Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line, JPN J CANC, 91(4), 2000, pp. 439-445
Citations number
31
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
JAPANESE JOURNAL OF CANCER RESEARCH
ISSN journal
09105050 → ACNP
Volume
91
Issue
4
Year of publication
2000
Pages
439 - 445
Database
ISI
SICI code
0910-5050(200004)91:4<439:PIWAOO>2.0.ZU;2-Z
Abstract
Overcoming multidrug resistance (MDR) is an urgent issue to improve the pro gnosis of osteosarcoma patients. In this study, we undertook to clarify the effect of photodynamic therapy (PDT) with acridine orange (AO) on the MDR mouse osteosarcoma (MOS/ADR1) cell line, by comparing the outcome with the effect on a chemosensitive osteosarcoma (MOS) cell line. Cultured cells of MOS and MOS/ADR1 cell lines were exposed to AO at various concentrations fo r various times, followed by long- or short-term (10 or 1 min) illumination with blue light (466.5 nm) for excitation. Living cells were counted by me ans of the trypan blue exclusion test. The results showed that AO rapidly b ound to DNA, RNA and lysosomes of living MOS and MOS/ADR1 cells and also th at most tumor cells in both cell lines died rapidly (viability ratio to unt reated cells: 1/1000) within 48 h under conditions of continuous or 15-min flash exposure to AO at concentrations above 1.0 mu g/ mi plus 10-min illum ination with blue light. Even after flash exposure to AO at concentrations above 1.0 mu g/ml plus 1-min illumination, the viability of MOS/ADR1 cells decreased to a viability ratio of less than 1/1000 within 72 h, Based on th ese results, we concluded that AO with photoexcitation has a strong cytocid al effect, not only on chemosensitive mouse osteosarcoma cells, but also on MDR mouse osteosarcoma cells. These results suggested that photodynamic th erapy with AO may be a new approach to treating MDR human osteosarcomas.